Posters & Presentations

• Novel Mechanisms of Action for HDAC Inhibitors Point the Way to Novel Indications. [Seminar] 2nd Annual HDAC Inhibitors Conference: Targeting Oncology Close and Beyond, at CHI Discovery on Target 2008, Boston, MA, 22-23 October 2008.
• The histone deacetylase-8 (HDAC8) selective inhibitor PCI-34051 decreases interleukin-1 beta secretion in vitro and reduces inflammation in vivo. [Poster] ASH 2008 Annual Meeting, San Francisco, CA, 6-9 December 2008.
• Phase I Analysis of the Safety and Pharmacodynamics of the Broad Spectrum Histone Deacetylase Inhibitor (HDACi) PCI-24781 in Relapsed and Refractory Lymphoma [Poster] ASH 2009 Annual Meeting, New Orleans, LA, 5-8 December 2009.

Scientific Manuscripts

• Adimoolam S, Sirisawad M, Chen J, Thiemann P, Ford J, Buggy J. HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination. Proc Natl Acad Sci U S A. Dec 2007;104(49):19482-19487.
• Adimoolam S, Sirisawad M, Chen J, Thiemann P, Ford J, Buggy J. HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination. Proc Natl Acad Sci U S A. Dec 2007;104(49):19482-19487.
• Balasubramanian S, Ramos J, Luo W, Sirisawad M, Verner E, Buggy J. A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia. May 2008;22(5):1026-1034.
• Balasubramanian S, Steggerda S, Sirisawad M, Buggy J. The histone deacetylase 8-selective inhibitor PCI-34051 blocks IL-1beta secretion in vitro and reduces inflammation in vivo. Manuscript in preparation.
• Banuelos C, Banáth J, MacPhail S, Zhao J, Reitsema T, Olive P. Radiosensitization by the histone deacetylase inhibitor PCI-24781. Clin Cancer Res. Nov 2007;13(22 Pt 1):6816-6826.
• Blanchard F, Chipoy C. Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases? Drug Discov Today. Feb 2005;10(3):197-204.
• Buggy J, Cao Z, Bass K, et al. CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo. Mol Cancer Ther. May 2006;5(5):1309-1317.
• Buggy J, Sideris M, Mak P, Lorimer D, McIntosh B, Clark J. Cloning and characterization of a novel human histone deacetylase, HDAC8. Biochem J. Aug 2000;350 Pt 1:199-205.
• Elaut G, Rogiers V, Vanhaecke T. The pharmaceutical potential of histone deacetylase inhibitors. Curr Pharm Des. 2007;13(25):2584-2620.
• Farasat S, Aksentijevich I, Toro J. Autoinflammatory diseases: clinical and genetic advances. Arch Dermatol. Mar 2008;144(3):392-402.
• Gray S, Dangond F. Rationale for the use of histone deacetylase inhibitors as a dual therapeutic modality in multiple sclerosis. Epigenetics.1(2):67-75.
• Kazantsev A, Thompson L. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat Rev Drug Discov. Oct 2008;7(10):854-868.
• Lequerré T, Quartier P, Rosellini D, et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis. Mar 2008;67(3):302-308.
• Oehme I, Deubzer H, Wegener D, et al. Histone deacetylase 8 in neuroblastoma tumorigenesis. Clin Cancer Res. Jan 2009;15(1):91-99.
• Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med. May 2005;201(9):1479-1486.
• Somoza J, Skene R, Katz B, et al. Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure. Jul 2004;12(7):1325-1334.
• Steffan J, Bodai L, Pallos J, et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature. Oct 2001;413(6857):739-743.
• Susick L, Senanayake T, Veluthakal R, Woster P, Kowluru A. A novel histone deacetylase inhibitor prevents IL-1beta-induced metabolic dysfunction in pancreatic beta-cells. J Cell Mol Med. Jan 2009.